Q3 2026 --12-31 false 0000101295 false false false false 3 3 3 3 3 0 6 2 0 0 1 1 0.10 0.10 00001012952026-01-012026-09-30 thunderdome:item 00001012952026-07-012026-09-30 iso4217:USD 0000101295ug:O2025Q1DividendsMember2025-03-31 0000101295ug:O2025Q1DividendsMember2025-01-012025-03-31 iso4217:USDxbrli:shares 0000101295ug:O2025Q3DividendsMember2025-09-30 0000101295ug:O2025Q3DividendsMember2025-07-012025-09-30 0000101295ug:O2026Q1DividendsMember2026-03-31 0000101295ug:O2026Q1DividendsMember2026-01-012026-03-31 0000101295ug:O2026Q3DividendsMember2026-09-30 0000101295ug:O2026Q3DividendsMember2026-07-012026-09-30 00001012952025-01-012025-09-30 00001012952025-07-012025-09-30 xbrli:pure 0000101295us-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMemberug:ThreeRawMaterialVendorsMember2025-07-012025-09-30 0000101295us-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMemberug:ThreeRawMaterialVendorsMember2026-07-012026-09-30 0000101295us-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMemberug:ThreeRawMaterialVendorsMember2025-01-012025-09-30 0000101295us-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMemberug:ThreeRawMaterialVendorsMember2026-01-012026-09-30 0000101295us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2025-01-012025-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2025-01-012025-09-30 0000101295ug:DistributorMember2025-01-012025-09-30 0000101295us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2026-01-012026-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2026-01-012026-09-30 0000101295ug:DistributorMember2026-01-012026-09-30 0000101295us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2025-07-012025-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2025-07-012025-09-30 0000101295us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2026-07-012026-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2026-07-012026-09-30 0000101295ug:DistributorMember2026-07-012026-09-30 00001012952025-12-31 00001012952026-09-30 0000101295ug:AccountingAndTaxServicesMembersrt:DirectorMember2025-01-012025-09-30 0000101295ug:AccountingAndTaxServicesMembersrt:DirectorMember2025-07-012025-09-30 0000101295ug:AccountingAndTaxServicesMembersrt:DirectorMember2026-01-012026-09-30 0000101295ug:AccountingAndTaxServicesMembersrt:DirectorMember2026-07-012026-09-30 0000101295ug:DCPlanMember2025-01-012025-09-30 utr:Y 0000101295ug:DCPlanMemberug:DiscretionaryContributionsVestingEachAdditionalYearMember2026-01-012026-09-30 0000101295ug:DCPlanMemberug:DiscretionaryContributionsVestingAtTwoYearsMember2026-01-012026-09-30 0000101295ug:DCPlanMember2026-01-012026-09-30 0000101295us-gaap:USTreasuryBillSecuritiesMember2025-12-31 0000101295us-gaap:USTreasuryBillSecuritiesMember2026-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMembercountry:CN2025-01-012025-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMemberus-gaap:NonUsMember2025-01-012025-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMembercountry:CN2026-01-012026-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMemberus-gaap:NonUsMember2026-01-012026-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMembercountry:CN2025-07-012025-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMembercountry:CN2026-07-012026-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMemberus-gaap:NonUsMember2025-07-012025-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMemberus-gaap:NonUsMember2026-07-012026-09-30 0000101295us-gaap:NonUsMember2025-01-012025-09-30 0000101295us-gaap:NonUsMember2026-01-012026-09-30 0000101295us-gaap:NonUsMember2025-07-012025-09-30 0000101295us-gaap:NonUsMember2026-07-012026-09-30 0000101295country:US2025-01-012025-09-30 0000101295country:US2026-01-012026-09-30 0000101295country:US2025-07-012025-09-30 0000101295country:US2026-07-012026-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:CosmeticIngredientsMemberus-gaap:NonUsMember2025-01-012025-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:CosmeticIngredientsMemberus-gaap:NonUsMember2026-01-012026-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:CosmeticIngredientsMemberus-gaap:NonUsMember2025-07-012025-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:CosmeticIngredientsMemberus-gaap:NonUsMember2026-07-012026-09-30 0000101295ug:MedicalMember2025-01-012025-09-30 0000101295ug:MedicalMember2026-01-012026-09-30 0000101295ug:MedicalMember2025-07-012025-09-30 0000101295ug:MedicalMember2026-07-012026-09-30 0000101295ug:CosmeticIngredientsMember2025-01-012025-09-30 0000101295ug:CosmeticIngredientsMember2026-01-012026-09-30 0000101295ug:CosmeticIngredientsMember2025-07-012025-09-30 0000101295ug:CosmeticIngredientsMember2026-07-012026-09-30 0000101295ug:PharmaceuticalsMember2025-01-012025-09-30 0000101295ug:PharmaceuticalsMember2026-01-012026-09-30 0000101295ug:PharmaceuticalsMember2025-07-012025-09-30 0000101295ug:PharmaceuticalsMember2026-07-012026-09-30 0000101295us-gaap:DemandDepositsMember2025-12-31 0000101295us-gaap:DemandDepositsMember2026-09-30 00001012952025-09-30 00001012952024-12-31 0000101295us-gaap:RetainedEarningsMember2025-09-30 0000101295us-gaap:CommonStockMember2025-09-30 xbrli:shares 0000101295us-gaap:RetainedEarningsMember2025-07-012025-09-30 00001012952025-06-30 0000101295us-gaap:RetainedEarningsMember2025-06-30 0000101295us-gaap:CommonStockMember2025-06-30 00001012952025-04-012025-06-30 0000101295us-gaap:RetainedEarningsMember2025-04-012025-06-30 00001012952025-03-31 0000101295us-gaap:RetainedEarningsMember2025-03-31 0000101295us-gaap:CommonStockMember2025-03-31 00001012952025-01-012025-03-31 0000101295us-gaap:RetainedEarningsMember2025-01-012025-03-31 0000101295us-gaap:RetainedEarningsMember2024-12-31 0000101295us-gaap:CommonStockMember2024-12-31 0000101295us-gaap:RetainedEarningsMember2026-09-30 0000101295us-gaap:CommonStockMember2026-09-30 0000101295us-gaap:RetainedEarningsMember2026-07-012026-09-30 00001012952026-06-30 0000101295us-gaap:RetainedEarningsMember2026-06-30 0000101295us-gaap:CommonStockMember2026-06-30 00001012952026-04-012026-06-30 0000101295us-gaap:RetainedEarningsMember2026-04-012026-06-30 00001012952026-03-31 0000101295us-gaap:RetainedEarningsMember2026-03-31 0000101295us-gaap:CommonStockMember2026-03-31 00001012952026-01-012026-03-31 0000101295us-gaap:RetainedEarningsMember2026-01-012026-03-31 0000101295us-gaap:RetainedEarningsMember2025-12-31 0000101295us-gaap:CommonStockMember2025-12-31 00001012952026-11-02
 

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

 

(Mark One)

 

☑

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐

 TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

COMMISSION FILE NUMBER: 1-10526

 

UNITED-GUARDIAN, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware 11-1719724
(State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)

 

230 Marcus Boulevard, Hauppauge, New York 11788

(Address of Principal Executive Offices)

 

(631) 273-0900

(Registrant’s Telephone Number)

 

N/A

(Former name, former address, and former fiscal year, if changed since last report)

 

 

 

Cover Page 1 of 2

 

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.10 par value per share

UG

NASDAQ Global Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.                                                       

Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).                                                                                           

Yes ☑ No ☐

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐   Accelerated filer ☐  
  Non-accelerated filer ☑    Smaller reporting company ☑  
      Emerging growth company ☐  

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)          

 

Yes ☐ No ☑

 

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

 

As of November 2, 2026, the Registrant had issued and outstanding 4,594,319 shares of Common Stock, $.10 par value per share ("Common Stock").

 

 

 

 

 

 

 

Cover Page 2 of 2

 

  

 

UNITED-GUARDIAN, INC.

 

INDEX TO FINANCIAL STATEMENTS

          Page No.

Part I. FINANCIAL INFORMATION

 
   

Item 1 - Condensed Financial Statements (unaudited unless indicated otherwise)

2
   

Statements of Income - Three and Nine Months ended September 30, 2026 and 2025

2

   

Balance Sheets – September 30, 2026 (unaudited) and December 31, 2025 (audited)

3-4

   

Statements of Changes in Stockholders’ Equity – Three and Nine Months ended September 30, 2026 and 2025

5

   

Statements of Cash Flows - Nine Months ended September 30, 2026 and 2025

6

   

Notes to Condensed Financial Statements

7-17

   

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations

17-23

   

Item 3 - Quantitative and Qualitative Disclosures About Market Risk

23
   

Item 4 - Controls and Procedures

23
   

Part II. OTHER INFORMATION

 
   

Item 1 - Legal Proceedings

24
   

Item 1A - Risk Factors

24
   

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds

24
   

Item 3 - Defaults Upon Senior Securities

24
   

Item 4 - Mine Safety Disclosures

24
   

Item 5 - Other Information

24
   

Item 6 - Exhibits

25
   

Signatures

26

 

 

 

 

Page 1 of 26

  

 

UNITED-GUARDIAN, INC.

 

Part I. FINANCIAL INFORMATION

 

ITEM 1. Condensed Financial Statements

 

STATEMENTS OF INCOME
(UNAUDITED)

 

   

THREE MONTHS ENDED
SEPTEMBER 30,

   

NINE MONTHS ENDED

SEPTEMBER 30,

 
   

2026

   

2025

   

2026

   

2025

 

Net sales

  $ 3,494,780     $ 2,264,261     $ 9,475,269     $ 7,583,613  
                                 

Costs and expenses:

                               

Cost of sales

    1,619,479       1,311,192       4,629,733       3,775,122  

Operating expenses

    644,539       620,893       1,978,784       1,947,678  

Research and development expense

    121,834       117,104       361,250       339,366  

Total costs and expenses

    2,385,852       2,049,189       6,969,767       6,062,166  

Income from operations

    1,108,928       215,072       2,505,502       1,521,447  
                                 

Other Income:

                               

Investment income

    72,556       75,165       212,815       230,425  

Net (loss) gain on marketable securities

    (7,916 )     36,238       58,191       73,164  

Settlement income

    -       -       339,493       -  

Gain on sale of asset

    -       -       8,310       -  

Total other income

    64,640       111,403       618,809       303,589  

Income before provision for income taxes

    1,173,568       326,475       3,124,311       1,825,036  
                                 

Provision for income taxes

    242,656       58,034       645,918       368,874  

Net income

  $ 930,912     $ 268,441     $ 2,478,393     $ 1,456,162  
                                 

Earnings per common share (Basic and Diluted)

  $ 0.20     $ 0.06     $ 0.54     $ 0.32  
                                 

Weighted average shares (Basic and Diluted)

    4,594,319       4,594,319       4,594,319       4,594,319  

 

 

See Notes to Condensed Financial Statements

 

Page 2 of 26

 

 

UNITED-GUARDIAN, INC.

 

BALANCE SHEETS

 

ASSETS

 

   

 

SEPTEMBER 30,

2026

      DECEMBER 31,
2025
 
   

(UNAUDITED)

     

 (AUDITED)

 

Current assets:

               

Cash and cash equivalents

  $ 1,407,803     $ 1,251,097  

Marketable securities

    7,336,917       7,322,646  

Accounts receivable, net of allowance for credit losses of $29,069 at September 30, 2026 and $17,169 at December 31, 2025

    2,392,059       1,586,889  

Inventories, net

    1,124,306       1,507,763  

Prepaid expenses and other current assets

    146,078       207,839  

Prepaid income taxes

    175,438       325,163  

Total current assets

    12,582,601       12,201,397  

Net property, plant, and equipment:

               

Land

    69,000       69,000  

Factory equipment and fixtures

    4,784,710       4,786,309  

Building and improvements

    3,374,630       3,352,276  

Total property, plant, and equipment

    8,228,340       8,207,585  

Less: Accumulated depreciation

    7,362,949       7,300,403  

Total property, plant, and equipment, net

    865,391       907,182  
                 

TOTAL ASSETS

  $ 13,447,992     $ 13,108,579  

 

See Notes to Condensed Financial Statements

 

Page 3 of 26

 

UNITED-GUARDIAN, INC.

 

BALANCE SHEETS

(continued)

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

    SEPTEMBER 30,     DECEMBER 31,  
   

2026

   

2025

 

Current liabilities:

 

(UNAUDITED)

   

(AUDITED)

 

Accounts payable

  $ 489,719     $ 480,791  

Accrued expenses

    1,309,999       1,164,948  

Deferred revenue

    128,651       12,177  

Dividends payable

    8,468       11,405  

Total current liabilities

  $ 1,936,837     $ 1,669,321  
                 

Deferred income taxes, net

    327,626       207,246  
                 

Total liabilities

  $ 2,264,463     $ 1,876,567  
                 

Commitments and contingencies

           
                 

Stockholders’ equity:

               

Common stock (at $.10 par value) (10,000,000 shares authorized; 4,594,319 shares issued and outstanding at September 30, 2026 and December 31, 2025)

    459,432       459,432  

Retained earnings

    10,724,097       10,772,580  

Total stockholders’ equity

    11,183,529       11,232,012  
                 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

  $ 13,447,992     $ 13,108,579  

 

See Notes to Condensed Financial Statements

 

Page 4 of 26

 

 

UNITED-GUARDIAN, INC.

 

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

 

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026

 

    Common stock     Retained          
    Shares     Amount     Earnings     Total  

Balance, January 1, 2026

    4,594,319     $ 459,432     $ 10,772,580     $ 11,232,012  

Net income

    -       -       818,902       818,902  

Dividends declared and paid ($0.25 per share)

    -       -       (1,148,536 )     (1,148,536 )

Dividends declared, not paid ($0.25 per share)

    -       -       (44 )     (44 )

Balance, March 31, 2026

    4,594,319     $ 459,432     $ 10,442,902     $ 10,902,334  

Net income

    -       -       728,579       728,579  

Balance, June 30, 2026

    4,594,319     $ 459,432     $ 11,171,481     $ 11,630,913  

Net income

    -       -       930,912       930,912  

Dividends declared and paid ($0.30 per share)

    -       -       (1,378,267 )     (1,378,267 )

Dividends declared, not paid ($0.30 per share)

    -       -       (29 )     (29 )

Balance, September 30, 2026

    4,594,319     $ 459,432     $ 10,724,097     $ 11,183,529  

 

 

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025

 

    Common stock     Retained          
    Shares     Amount     Earnings     Total  

Balance, January 1, 2025

    4,594,319     $ 459,432     $ 11,423,434     $ 11,882,866  

Net income

    -       -       560,895       560,895  

Dividends declared and paid ($0.35 per share)

    -       -       (1,607,893 )     (1,607,893 )

Dividends declared, not paid ($0.35 per share)

    -       -       (119 )     (119 )

Balance, March 31, 2025

    4,594,319     $ 459,432     $ 10,376,317     $ 10,835,749  

Net income

    -       -       626,826       626,826  

Balance, June 30, 2025

    4,594,319     $ 459,432     $ 11,003,143     $ 11,462,575  

Net income

    -       -       268,441       268,441  

Dividends declared and paid ($0.25 per share)

    -       -       (1,148,536 )     (1,148,536 )

Dividends declared, not paid ($0.25 per share)

    -       -       (44 )     (44 )

Balance, September 30, 2025

    4,594,319     $ 459,432     $ 10,123,004     $ 10,582,436  

 

 

 

 

 

 

See Notes to Condensed Financial Statements

 

Page 5 of 26

 

 

UNITED-GUARDIAN, INC.

 

STATEMENTS OF CASH FLOWS
(UNAUDITED)

 

   

NINE MONTHS ENDED

 
   

SEPTEMBER 30,

 

Cash flows from operating activities:

 

2026

   

2025

 

Net income

  $ 2,478,393     $ 1,456,162  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Depreciation and amortization

    86,396       77,485  

Net gain on marketable securities

    (58,191 )     (73,164 )

Gain on sale of asset

    (8,310 )     -  

Allowance for credit losses

    11,900       (250 )

Change in allowance for obsolete inventory

    (8,000 )     (2,786 )

Deferred income taxes

    120,380       157,303  

(Increase) decrease in operating assets:

               

Accounts receivable

    (817,070 )     267,002  

Inventories

    391,457       46,078  

Prepaid expenses and other current assets

    61,761       54,135  

Prepaid income taxes

    149,725       (39,209 )

Increase (decrease) in operating liabilities:

               

Accounts payable

    8,928       (180,039 )

Accrued expenses

    145,051       (126,393 )

Deferred revenue

    116,474       -  

Net cash provided by operating activities

    2,678,894       1,636,324  

Cash flows from investing activities:

               

Acquisition of property, plant and equipment

    (44,605 )     (36,456 )

Proceeds from sale of asset

    8,310       -  

Proceeds from sale of marketable securities

    12,466,846       12,294,942  

Purchases of marketable securities

    (12,422,926 )     (12,142,909 )

Net cash provided by investing activities

    7,625       115,577  

Cash flows from financing activities:

               

Dividends paid

    (2,529,813 )     (2,766,720 )

Net cash used in financing activities

    (2,529,813 )     (2,766,720 )

Net increase (decrease) in cash and cash equivalents

    156,706       (1,014,819 )
                 

Cash and cash equivalents at beginning of period

    1,251,097       1,875,655  

Cash and cash equivalents at end of period

  $ 1,407,803     $ 860,836  

Supplemental disclosure of cash flow information:

               

Taxes paid

  $ 375,813     $ 250,780  

Supplemental disclosure of non-cash items:

               

Dividends payable

  $ 73     $ 163  

 

See Notes to Condensed Financial Statements

 

Page 6 of 26

 

UNITED-GUARDIAN, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

 

 

 

1.

Business

 

United-Guardian, Inc. (“Company”) is a diversified life sciences and personal care ingredients company that develops, manufactures and globally commercializes proprietary pharmaceuticals, medical lubricants, specialty cosmetic ingredients, and consumer wellness products. The Company is incorporated in the State of Delaware. Our Research and Development (“R&D”) department primarily develops new and unique specialty cosmetic and sexual wellness ingredients using natural and environmentally friendly raw materials, which is a priority for many of our personal care customers. The R&D department also modifies, refines, and expands the uses for existing products, with the goal of further developing the markets in which our products are used. All the products that the Company markets, except for Renacidin®, are produced at our facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for us by an outside contract manufacturer.

 

 

2.

Basis of Presentation

 

Interim condensed financial statements of the Company are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information, pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the three and nine months ended September 30, 2026 (also referred to as the "third quarter of 2026" and the "first nine months of 2026," respectively) are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2026. The interim unaudited condensed financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

 

 

3.

Segment Information

 

The Company operates its business under one operating segment, which is also its reportable segment. The President, who is the Company's chief operating decision maker (“CODM”), reviews financial information presented at the consolidated level and decides how to allocate resources based on financial metrics, including net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM, along with our Board of Directors, use such financial metrics, including net income, to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits or allocate them to other parts of the organization, such as working capital needs, mandatory and discretionary capital expenditures or other growth opportunities that may arise that are in our best interest and the best interest of our stockholders.

 

Net income, other financial metrics and sales forecasts are used to monitor budget versus actual results. The reported segment revenue, segment profit or loss and significant segment expenses are the same as the consolidated results disclosed on the consolidated statements of income.

 

Page 7 of 26

  

 

4.

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as revenues and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the reserve for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities, and the allocation of overhead.

 

 

5.

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with financially strong, Federal Deposit Insurance Corporation (“FDIC”) insured financial institutions, and it believes that any amounts above FDIC insurance limitations are at minimal risk. The amounts held in excess of FDIC limits at any point in time are considered temporary and are primarily due to the timing of maturities of United States (“U.S.”) Treasury Bills. Cash and cash equivalents held in these accounts are currently insured by the FDIC up to a maximum of $250,000. At September 30, 2026 and December 31, 2025, $219,329 and $1,300, respectively, exceeded the FDIC limit. The Company also invests in certain money market mutual funds that are protected as securities by the Securities Investor Protection Corporation (“SIPC”). At September 30, 2026 and December 31, 2025, cash held in these money market mutual funds of approximately $445,122 and $502,000, respectively, exceeded the SIPC limit.

 

The following table summarizes the Company's cash and cash equivalents:

     

    September 30,     December 31,  
   

2026

   

2025

 

Demand deposits

  $ 462,681     $ 248,997  

Money market funds

    945,122       1,002,100  

Total cash and cash equivalents

  $ 1,407,803     $ 1,251,097  

  

 

6.

Accounts Receivable and Reserves

 

The Company presents financial assets at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life. The Company performed its expected credit loss calculation based on historical accounts receivable write-offs, including consideration of then-existing economic conditions.

 

The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects the Company’s best estimate of the amounts that will not be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and is based on the Current Expected Credit Losses (“CECL”). At September 30, 2026, and December 31, 2025, the allowance for credit losses related to accounts receivable amounted to $29,069 and $17,169, respectively.

 

Page 8 of 26

  

 

7.

Revenue Recognition

 

The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. Our principal source of revenue is product sales.

 

Our sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of our pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with our current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

 

During 2026 and 2025, we participated in various government drug rebate programs related to the sale of Renacidin, our most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Manufacturer Discount Program (“MDP”) (formerly the Medicare Part D Coverage Gap Discount Program (“CGDP”)). These programs require us to sell our product at a discounted price, typically given in the form of a rebate. Our sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

On January 1, 2025, the Centers for Medicare & Medicaid Services (“CMS”) implemented a new Medicare Part D Manufacturer Discount Program (“Discount Program”), which replaced the prior CGDP. The new Discount Program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases, and lowers the cap on enrollee out-of-pocket costs. Under the new Discount Program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods and removal of the cap that was in place that limited the drug manufacturer’s liability. The overall financial impact of this new program will vary depending on the products being reimbursed but it is expected to increase Medicare Part D rebates for drug manufacturers.

 

The Company’s status as a “specified small manufacturer” by CMS, entitles us to a multi-year phase-in period during which we would pay a lower percentage discount on drugs dispensed to beneficiaries. Based on our current level of sales through the Medicare Part D Program, we have reduced rebate liabilities beginning in 2025, with rebates gradually increasing each year thereafter, until they reach their full phase-in by 2031. By the end of the phase in period in 2031, these rebate liabilities are expected to exceed the liabilities we have recorded under the CGDP in previous years.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, we recognize revenue from sales of most of our products when those products are shipped, which is when our performance obligation is satisfied. Our cosmetic, sexual wellness, and medical products are shipped EXW from our facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of our medical lubricant products are deemed final upon shipment, and we have no obligation to repurchase or allow the return of these goods unless they are defective. We consider sales of our pharmaceutical products to be final upon shipment unless (a) they are found to be defective; (b) the product is damaged or lost during shipping; (c) the product is too close to its expiration date for the customer to sell; or (d) the product is expired but is not more than one year past its expiration date. These return policies are in conformance with standard pharmaceutical industry practice. We estimate an allowance for outdated material returns based on previous years’ historical returns of our pharmaceutical products.

 

Page 9 of 26

 

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of our products is not contingent upon the customer being able to sell the goods to a third party.

 

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. At September 30, 2026 and December 31, 2025, the Company had allowances of $203,344 and $194,947, respectively, for possible outdated material returns, which is included in accrued expenses. There is no asset value associated with these outdated material returns, as these products are destroyed. We have not experienced significant fluctuations between estimated allowances and actual activity.

 

At September 30, 2026, the Company recorded advance payments from customers of $128,651, which are included in deferred revenue on the balance sheet. The related performance obligations associated with these payments are expected to be satisfied in the fourth quarter of 2026. At December 31, 2025, the Company recorded advance payments from customers of $12,177. The related performance obligations associated with these payments were satisfied in the first quarter of 2026.

 

The Company has distribution fee contracts with certain distributors of its pharmaceutical products that entitle them to distribution and service-related fees. The Company records distribution fees and estimates of distribution fees as offsets to revenue.

 

Disaggregated sales by product class are as follows:

 

    Three months ended     Nine months ended  
    September 30,     September 30,  
    2026     2025     2026     2025  

Pharmaceuticals

  $ 1,583,299     $ 1,230,087     $ 4,495,456     $ 3,848,474  

Cosmetic ingredients

    1,156,365       403,401       3,288,481       1,998,948  

Medical lubricants

    755,116       630,773       1,691,332       1,736,191  

Total Sales

  $ 3,494,780     $ 2,264,261     $ 9,475,269     $ 7,583,613  

 

The Company’s cosmetic ingredients are marketed worldwide by five distributors, of which U.S.-based Ashland Specialty Ingredients (“ASI”) purchases the largest volume. Approximately 23% of the Company’s total sales in the third quarter of 2026 were to customers located outside of the United States, compared with approximately 31% in the third quarter of 2025. For the nine months ended September 30, 2026, approximately 21% of the Company’s total sales were to customers located outside of the United States, compared with approximately 25% for the nine months ended September 30, 2025.

 

 

Page 10 of 26

 

Disaggregated sales by geographic region are as follows:

 

    Three months ended     Nine months ended  
    September 30,     September 30,  
    2026     2025     2026     2025  

United States*

  $ 2,706,388     $ 1,561,466     $ 7,514,514     $ 5,663,509  

Other countries

    788,392       702,795       1,960,755       1,920,104  

Total Sales

  $ 3,494,780     $ 2,264,261     $ 9,475,269     $ 7,583,613  

 

* Substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S. As a result, all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 81% of its sales of the Company’s products in the third quarter of 2026 were to foreign customers compared with 85% for the same period in 2025, with China representing approximately 31% of those foreign sales in the third quarter of 2026, compared with approximately 49% in the third quarter of 2025.

 

For the nine months ended September 30, 2026, approximately 75% of ASI’s sales of the Company’s products were to foreign customers, with China accounting for approximately 44% of those foreign sales. For the nine months ended September 30, 2025, approximately 79% of ASI’s sales were to foreign customers with China accounting for approximately 51% of those foreign sales.

 

 

8.

Accounting for Financial Instruments – Credit Losses

 

The Company performs ongoing credit evaluations of its customers and adjusts credit limits, as determined by a review of current credit information. In addition, the Company continuously monitors collection and payments from customers and maintains an allowance for credit losses based upon historical experience, anticipation of uncollectible accounts receivable and any specific customer collection issues that have been identified. While the Company’s credit losses have historically been low and within expectations, we may not experience the same credit loss rates that have historically been attained in the future. The receivables are highly concentrated in a relatively small number of customers. Therefore, a significant change in the liquidity, financial position, or willingness to pay timely, or at all, of any one of our significant customers would have a significant impact on our results of operations and cash flows.

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

 

 

9.

Marketable Securities

 

The Company’s marketable securities include investments in equity mutual funds and United States Treasury Bills (“U.S. Treasury Bills”) with maturities longer than 3 months. Our marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. U.S Treasury Bills are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. We evaluate our investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and our ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value.

 

 

Page 11 of 26

 

The disaggregated net gains and losses on the marketable securities recognized in the income statements for the three and nine months ended September 30, 2026 and 2025, respectively, are as follows:

 

    Three months ended     Nine months ended  
    September 30,     September 30,  
   

2026

   

2025

   

2026

    2025  

Net (losses) gains recognized during the period on marketable securities

  $ (7,916 )   $ 36,238     $ 58,191     $ 73,164  

Less: Net (gains) losses recognized during the period on marketable securities sold during the period

    -       -       (27,948 )     1,507  

Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date

  $ (7,916 )   $ 36,238     $ 30,243     $ 74,671  

 

The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:

 

•    Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

•    Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

•    Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company’s marketable equity securities, which are considered available for sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The Company’s fixed income U.S. Treasury Bills are considered held-to-maturity securities and are valued at amortized cost.

 

Page 12 of 26

 

The following tables summarize the Company’s investments:

 

September 30, 2026(Unaudited)

 

    Cost    

Fair Value

   

Unrealized Gain

 

Equity Securities:

                       

Equity and other mutual funds

  $ 754,770     $ 849,856     $ 95,086  
                         

Other short-term investments:

                       

U.S. Treasury Bills (original maturities > 3 months)

    6,487,061       6,487,061       -  

Total marketable securities

  $ 7,241,831     $ 7,336,917     $ 95,086  

 

December 31, 2025(Audited)

 

    Cost    

Fair Value

   

Unrealized Gain

 

Equity Securities:

                       

Equity and other mutual funds

  $ 713,120     $ 777,963     $ 64,843  
                         

Other short-term investments:

                       

U.S Treasury Bills (original maturities > 3 months)

    6,544,683       6,544,683       -  

Total marketable securities

  $ 7,257,803     $ 7,322,646     $ 64,843  

 

Investment income is recognized when earned and consists principally of dividend income from equity mutual funds and interest income from U.S. Treasury Bills and money market funds. Realized gains and losses on sales of investments are determined on a specific identification basis.

 

Proceeds from the sale and redemption of marketable securities amounted to $12,466,846 for the nine months ended September 30, 2026, with realized gains of $27,948 recognized on these sales. Proceeds from the sale and redemption of marketable securities amounted to $12,294,942 for the nine months ended September 30, 2025, with realized losses of $1,507 recognized on these sales.

 

 

10.

Inventories

 

   

September 30,

   

December 31,

 
   

2026

   

2025

 
   

(UNAUDITED)

   

(AUDITED)

 

Inventories consist of the following:

               

Raw materials

  $ 435,064     $ 442,993  

Work in process

    30,880       5,505  

Finished products

    658,362       1,059,265  

Total inventories

  $ 1,124,306     $ 1,507,763  

 

Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Finished product inventories at September 30, 2026 and December 31, 2025 are stated net of a reserve of $24,000 and $32,000, respectively, for slow moving and obsolete inventory.

 

Page 13 of 26

  

 

11.

Income Taxes

 

The Company’s tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, and as of September 30, 2026 and December 31, 2025, the Company did not have any unrecognized tax benefits. The Company’s provision for income taxes for the three and nine months ended September 30, 2026 and 2025 includes the following:

 

 

    Three months ended     Nine months ended  
    September 30,     September 30,  
    2026     2025     2026     2025  

Provision for federal income taxes - current

  $ 139,381     $ 154,434     $ 524,725     $ 210,758  

Provision for state income taxes - current

    -       -       813       813  

Provision for (benefit from) federal income taxes – deferred

    103,275       (96,400 )     120,380       157,303  

Total provision for income taxes

  $ 242,656     $ 58,034     $ 645,918     $ 368,874  

  

 

12.

Defined Contribution Plan

 

The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee’s pay that is deferred by the employee. Employees become fully vested in employer matching contributions immediately.

 

The Company can also elect to make discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the DC Plan under current IRS regulations. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment.

 

The Company accrued $60,000 and $86,250 in contributions to the DC Plan at September 30, 2026 and 2025, respectively. In the first nine months of 2026, there were no discretionary contributions made to the DC Plan. This was due to the Company’s Board of Directors electing not to fund a discretionary contribution for the year ended December 31, 2025, based on reduced sales and earnings. During the first nine months of 2025, the Company made discretionary contributions of $115,000 to the DC Plan. This payment represented the Company’s 2024 accrued discretionary contributions.

 

 

13.

Related-Party Transactions

 

For the three-and nine-month periods ended September 30, 2026, the Company made payments of $4,399 and $18,630, respectively, to the accounting firm PKF O’Connor Davies (“PKF”), for accounting and tax services. For the three- and nine-month periods ended September 30, 2025, the Company made payments of $9,640 and $13,640, respectively, to the accounting firm PKF O’Connor Davies (“PKF”) for accounting and tax services. Lawrence Maietta, a former partner at PKF, is a director of the Company and is currently serving as a senior consultant at PKF.

 

Page 14 of 26

  

 

14.

Other Information

 

Accrued Expenses

 

Accrued expenses consist of the following:

 

    September 30,     December 31  
    2026     2025  

Accrued Expenses

 

(Unaudited)

   

(Audited)

 

Bonuses

  $ 203,889     $ 182,383  

Distribution fees

    466,199       463,331  

Payroll and related expenses

    125,865       90,151  

Reserve for outdated material

    203,344       194,947  

Company 401(k) contribution

    60,000       -  

Audit fee

    65,133       72,708  

Annual report expenses

    55,335       80,387  

Sales rebates

    80,561       55,983  

Waste disposal costs

    27,000       13,765  

Insurance

    8,082       -  

Other

    14,591       11,293  

Total Accrued Expenses

  $ 1,309,999     $ 1,164,948  

  

 

15.

Recent Accounting Pronouncements

 

On November 4, 2024, the FASB issued ASU 2024-03 “Disaggregation of Income Statement Expenses” (“DISE”). This guidance requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. Subsequently issued ASU 2025-01 clarified the effective date of this standard. This guidance is effective for annual reporting periods beginning after December 15, 2026, and for interim periods, within annual reporting periods beginning after December 15, 2027.

 

 

16.

Concentrations of Credit Risk

 

Customer concentration - Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history and its overall credit worthiness to determine how much credit to allow or whether credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its credit risk from accounts receivable has been reduced.

 

Page 15 of 26

 

For the three months ended September 30, 2026, the Company’s largest cosmetic ingredient distributor, along with three of its pharmaceutical distributors, together accounted for 76% of the Company’s gross sales and 85% of its outstanding accounts receivable at September 30, 2026. During the three months ended September 30, 2025, the same cosmetic ingredient distributor and three pharmaceutical distributors together accounted for 69% of the Company’s gross sales and 81% of its outstanding accounts receivable at September 30, 2025.

 

For the nine months ended September 30, 2026, the Company’s largest cosmetic ingredient distributor, along with three of its pharmaceutical distributors, together accounted for 78% of the Company’s gross sales and 85% of its outstanding accounts receivable at September 30, 2026. During the nine months ended September 30, 2025, the same cosmetic ingredient distributor and three pharmaceutical distributors together accounted for 72% of the Company’s gross sales and 81% of its outstanding accounts receivable at September 30, 2025.

 

 

17.

Supplier Concentration

 

Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals that are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times.

 

For the three months ended September 30, 2026, the Company had three major raw material suppliers that collectively accounted for approximately 93% of the raw material purchases made by the Company. For the three months ended September 30, 2025, the same three major raw material suppliers collectively accounted for approximately 97% of the raw material purchases made by the Company.

 

For the nine months ended September 30, 2026, the Company had three major raw material suppliers that collectively accounted for approximately 87% of the raw material purchases made by the Company. During the first nine months of 2025, the same three major raw material suppliers collectively accounted for approximately 79% of the raw material purchases made by the Company. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of one of its pharmaceutical products, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream.

 

 

18.

Earnings Per Share

 

Basic earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.

 

Per share basic and diluted earnings were $0.20 and $0.06 for the three months ended September 30, 2026 and 2025, respectively, and $0.54 and $0.32 for the nine months ended September 30, 2026 and 2025, respectively.

 

Page 16 of 26

  

 

19.

Dividends

 

On July 14, 2026, the Company’s Board of Directors declared a cash dividend of $0.30 per share, which was paid on August 4, 2026 to all holders of record as of July 28, 2026. Dividends totaling $1,378,267 were paid on August 4, 2026, leaving a balance of $29 that was not paid. This $29 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 

On January 26, 2026, the Company’s Board of Directors declared a cash dividend of $0.25 per share, which was paid on February 17, 2026 to all holders of record as of February 9, 2026. During the first quarter of 2026, the Company declared a total of $1,148,580 in dividends, of which $1,148,536 was paid on February 17, 2026, leaving a balance of $44 that was not paid. This $44 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 

In addition, during the quarter ended September 30, 2026, the Company made payments of $1,654 in dividends in arrears to shareholders who had either converted their Guardian Chemical shares to United-Guardian, Inc. shares or whose shares had been escheated.

 

On July 11, 2025, the Company’s Board of Directors declared a cash dividend of $0.25 per share, which was paid on August 1, 2025 to all holders of record as of July 25, 2025. Dividends totaling $1,148,536 were paid on August 1, 2025, leaving a balance of $44 that was not paid. This $44 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 

On January 27, 2025, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on February 18, 2025 to all holders of record as of February 10, 2025. During the first quarter of 2025, the Company declared a total of $1,608,012 in dividends, of which $1,607,893 was paid on February 18, 2025, leaving a balance of $119 was not paid. This $119 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 

 

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

FORWARD-LOOKING STATEMENTS

 

You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.

 

Page 17 of 26

 

EXECUTIVE OVERVIEW

 

We are a diversified life sciences and personal care ingredients company that develops, manufactures and globally commercializes proprietary pharmaceuticals, medical lubricants, specialty cosmetic ingredients and consumer wellness products. With a long-standing reputation for delivering high-quality specialty products, we are committed to serving diverse markets with innovative solutions.

 

In January 2026, we entered into a new distribution agreement with Brenntag Specialties, a global market leader in chemicals and ingredients distribution, for the distribution of our new Natrajel® line of sexual wellness ingredients in the United States, Canada, and Mexico, and the distribution of Lubrajel® and Natrajel products in France. The new agreement provides an opportunity to grow the French market, which is known for innovation in personal care products.

 

In the third quarter of 2026, there were modest sales of our sexual wellness products. Although sales of this product line are just beginning, we are optimistic as to the potential this market offers. The sexual wellness segment is expected to grow at a higher compound annual growth rate (“CAGR”) than other segments such as skin care, personal care and cosmetics.

 

With a refined product portfolio and strategic partnerships, we are well-positioned for future growth, leveraging our expertise in specialty ingredients to capitalize on emerging market opportunities.

 

In 2025, we launched an insurance payer outreach program with the goal of having Renacidin, our most important pharmaceutical product, included on additional drug formularies. As a result of this effort, we received approval from two major Pharmacy Benefit Managers (“PBM’s”) for inclusion on their formularies. One of these PBM’s began including Renacidin on its formulary effective June 1, 2026, and the other on July 1, 2026.

 

During the third quarter of 2026, we saw a significant increase in gross sales of Renacidin, and believe that that increase was partially attributable to the inclusion of the product on these PBM formularies. While we will continue our insurance payer outreach as we move through 2026, we will also introduce a new outreach program with the focus on increasing awareness among healthcare professionals in order to further grow the market for Renacidin.

 

MACROECONOMIC AND GEOPOLITICAL CONDITIONS

 

A substantial portion of our product portfolio is manufactured and distributed domestically within the United States. While our domestic production footprint insulates these sales from direct cross-border import tariffs, our operating margins remain sensitive to fluctuations in global energy markets and petrochemical supply chains. Geopolitical volatility and supply disruptions in major oil- and gas-producing regions, including the Middle East and Eastern Europe, have historically contributed to increased freight surcharges and higher costs for petroleum-derived raw materials and packaging supplies. Significant or prolonged inflation in these input costs, if we are unable to fully pass them along to customers through selling price adjustments, could compress our gross margins and adversely affect our results of operations.

 

Page 18 of 26

 

A meaningful portion of our consolidated revenues is generated from international sales to overseas markets, including key distribution channels in Asia. Consequently, our financial condition and international growth prospects are vulnerable to shifts in trade relations, regional economic conditions, and foreign regulatory policies. The changes in U.S. trade policies and retaliatory tariff measures or non-tariff barriers imposed by foreign trade partners, particularly in key Asian markets, could directly increase the landed cost of our products for international customers. Higher effective duty rates may reduce our price competitiveness relative to local suppliers or prompt customers to seek alternative formulations. While we monitor international tariff exemption processes and local import regulations, any escalation in retaliatory tariffs, changes in local duty waivers, or heightened trade restrictions targeting American chemical products could lead to reduced export sales volumes, margin compression, and diminished cash flows from international operations.

 

CRITICAL ACCOUNTING POLICIES

 

As disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in conformity with US GAAP. The preparation of those financial statements required us to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues, and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. Our most critical accounting policies relate to revenue recognition, concentration of credit risk, investments, inventory, and income taxes. Since December 31, 2025, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.

 

The following discussion and analysis cover material changes in our financial condition since the year ended December 31, 2025, and a comparison of the results of operations for the three and nine months ended September 30, 2026 and September 30, 2025. This discussion and analysis should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2025. All references in this quarterly report to “sales” or “Sales” shall mean Net Sales unless specified otherwise.

 

In accordance with ASU-2016-13, we recognize an allowance for credit losses for financial assets carried at amortized cost to present the net amount expected to be collected as of the balance sheet date. Such allowance is based on the credit losses expected to arise over the life of the asset.

 

RESULTS OF OPERATIONS

 

Net Sales

 

Net sales for the third quarter of 2026 increased by $1,230,519 (54%) when compared with the same period in 2025. Net sales for the first nine months of 2026 increased by $1,891,656 (25%) as compared with the corresponding period in 2025. The increase in sales for the third quarter of 2026 and the first nine months of 2026 was attributable to changes in sales of the following product lines:

 

Page 19 of 26

 

Pharmaceuticals:

 

Because there are fees, rebates and allowances associated with sales of the Company’s two pharmaceutical products, Renacidin and Clorpactin® WCS-90, discussion of the Company’s pharmaceutical sales includes references to both gross sales (before fees, rebates and allowances) and net sales (after fees, rebates and allowances).

 

Gross sales of the Company’s pharmaceutical products for the three-and nine-month periods ended September 30, 2026 increased by $355,154 (24%) and $686,260 (15%), respectively, compared to the same periods in 2025. The increase for both periods was due to increases in gross sales of both Renacidin and Clorpactin WCS-90. Gross sales of Renacidin increased by $332,768 (26%) for the three-month period and $645,519 (16%) for the nine-month period. Gross sales of Clorpactin WCS-90 increased by $22,386 (13%) for the three-month period and $40,741 (9%) for the nine-month period. The Company believes the increase in sales of Renacidin was partially attributable due to the increased formulary coverage that began in the third quarter of 2026. The increase in sales of Clorpactin WCS-90 was due to normal fluctuations in customer ordering patterns.

 

With the benefits from our insurance payer outreach program starting to take shape, we are hopeful that the new formulary wins, combined with the focus on increasing awareness of Renacidin among healthcare professionals, will continue to create increased demand for Renacidin.

 

Net sales of the Company’s pharmaceutical products for the three- and nine-month periods ended September 30, 2026, saw a similar pattern, increasing by $353,212 (29%) for the three-month period and increasing by $646,982 (17%) for the nine-month period, with those increases due primarily to the reasons noted above.

 

The difference between the change in net sales compared with the change in gross sales for these products is due to a combination of the change in gross sales of those products as well as changes in pharmaceutical sales allowances related to the sales of these products. Typically, these allowances are directly related to the sales of these products. For the three- and nine-month periods ended September 30, 2026, sales allowances related to the Company’s pharmaceutical products increased by $1,941 (less than 1%) and $39,278 (4%), respectively, which were primarily related to increases in Medicare Part D rebates, VA rebates, and distribution fees.

 

Cosmetic ingredients:

 

 

(a)

Third quarter sales: For the third quarter of 2026, the Company’s sales of cosmetic ingredients increased by $752,964 (187%) when compared with the third quarter of 2025. The increase in third quarter sales was due primarily to an increase of $765,482 (275%) in sales of the Company’s cosmetic products to ASI. This increase was primarily due to ASI continuing to resume regular purchases of the Company’s products after experiencing an overstock situation in 2025.

 

Third quarter sales in 2026 to the Company’s four other distributors, as well as two direct cosmetic ingredient customers, decreased by a net of $12,518 (10%) compared with the third quarter of 2025. This sales decrease was primarily due to decreases in sales to our distributors in France and the United Kingdom.

 

Page 20 of 26

 

 

(b)

Nine-month sales: For the first nine months of 2026, the Company’s sales of cosmetic ingredients increased by $1,289,533 (65%) when compared with the same period in 2025. This increase was due primarily to an increase of $1,254,863 (84%) in sales to ASI, which was due to the same reason discussed above.


Cosmetic ingredient sales for the first nine months of the year to the Company’s four other cosmetic distributors, as well as to two direct cosmetic customers, increased by a net of $34,670 (7%) compared with the same period in 2025. This sales increase was primarily due to the increased orders from our new distributor in Korea.

 

Medical lubricants:

 

Sales of the Company’s medical lubricants increased by $124,343 (20%) for the three-month period ended September 30, 2026, compared with the same period in 2025, while sales for the nine-month period decreased by $44,859 (3%), compared with the same period in 2025. The increase in medical lubricant sales for the three-month period was due to an increase in orders from one of our larger customers in India. The decrease for the nine-month period was due to normal fluctuations in customer ordering patterns.

 

Cost of Sales

 

Cost of sales as a percentage of sales decreased to 46% in the third quarter of 2026, down from 58% in the third quarter of 2025. For the first nine months of 2026, cost of sales as a percentage of sales decreased to 49%, down from 50% in 2025. The decrease for the three-month period was the result of recognizing the benefit of lower per unit overhead costs on units sold in the third quarter of 2026 due to increased production.

 

Operating Expenses

 

Operating expenses, consisting of selling and general and administrative expenses, increased by $23,646 (4%) for the third quarter of 2026 compared with the equivalent period in 2025 and increased by $31,106 (2%) for the first nine months of 2026, compared with the equivalent period in 2025. The increase in operating expenses for both periods was due primarily to increases in sales and marketing expenses and payroll and payroll-related expenses.

 

Research and Development Expenses

 

Research and development expenses increased by $4,730 (4%) for the third quarter of 2026 and increased by $21,884 (6%) for the first nine months of 2026 compared with the same periods in 2025. The increases for both periods were primarily due to an increase in payroll and payroll-related expenses.

 

Investment Income

 

Investment income decreased by $2,609 (3%) and $17,610 (8%) for the three- and nine-month periods, respectively, ending September 30, 2026, compared with the equivalent periods in 2025. The decrease in both periods was primarily due to a decrease in interest income from investments in U. S. Treasury Bills due to lower interest rates in the first nine months of 2026 compared to the same period 2025.

 

Page 21 of 26

 

Net (Loss) Gain on Marketable Securities

 

The net change in the value of marketable securities decreased from a gain of $36,238 for the third quarter ending September 30, 2025 to a loss of $7,916 for the third quarter ending September 30, 2026. For the nine-month period ended September 30, 2026, the net gain decreased from $73,164 to $58,191. These decreased gains were due to normal market fluctuations. The Company’s management and Board of Directors continue to closely monitor the Company's investment portfolio and have made, and will continue to make, any changes they believe may be necessary or appropriate to minimize the future impact of global market volatility on the Company’s financial position.

 

Settlement Income

 

Included in net income for the nine-month period ended September 30, 2026, is a monetary settlement paid to us by the contract manufacturer (“CM”) of our pharmaceutical product Renacidin. The settlement relates to the unexpected shutdown of the CM’s facility during the latter part of 2023 and in the beginning of 2024. During this time, we were unable to fill complete orders of Renacidin. On October 27, 2023, we notified the CM of our intention to file a claim for damages in connection with the CM’s breach of our supply contract with the CM, and we requested compensation for the loss of sales during the shutdown period. The settlement, which was agreed upon by both parties, called for the CM to supply us with a specified volume of product at no cost. The product covered by this agreement was received at our facility in the first and second quarters of 2026 and was valued at $339,493. As of the date of this report, the CM has fulfilled their full obligation under the agreement, and there are no additional monies owed to the Company.

 

Provision for Income Taxes

 

The Company's effective income tax rate was 21% for the first nine-months of 2026 and 20% for the same period in 2025. The Company’s tax rate is expected to remain at 21% for the current fiscal year.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Working capital increased from $10,532,076 at December 31, 2025 to $10,645,764 at September 30, 2026, an increase of $113,688. The current ratio decreased from 7.3 to 1 at December 31, 2025 to 6.5 to 1 at September 30, 2026. The increase in working capital was primarily due to an increase in accounts receivable. The decrease in the current ratio was primarily due to increases in accrued expenses and deferred revenue.

 

The Company believes that its working capital is, and will continue to be, sufficient to support its operating requirements for at least the next twelve months.

 

The Company generated cash from operations of $2,678,894 and $1,636,324 for the nine months ended September 30, 2026 and September 30, 2025, respectively. The increase in cash from operations was primarily due to an increase in net income.

 

Cash provided by investing activities was $7,625 and $115,577 for the nine-month period ended September 30, 2026 and September 30, 2025, respectively. The decrease was due to some proceeds from the sale of marketable securities during the first nine months of 2025 not being reinvested. For the nine-month period ended September 30, 2026, a majority of these proceeds were reinvested in U.S. Treasury Bills.

 

Page 22 of 26

 

Cash used in financing activities was $2,529,813 and $2,766,720 for the nine-month period ended September 30, 2026 and September 30, 2025, respectively. The decrease was due to the payment of lower dividends in the first nine months of 2026 compared to the same period in 2025. We declared dividends of $0.55 per share for the nine-month period ended September 30, 2026, compared to $0.60 per share for the same period in 2025.

 

The Company expects to continue to use its cash to make dividend payments, to purchase marketable securities, and to take advantage of growth opportunities that are in the best interest of the Company and its shareholders.

 

OFF BALANCE-SHEET ARRANGEMENTS

 

The Company has no off balance-sheet transactions that have, or are reasonably likely to have, a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

 

The information to be reported under this item is not required of smaller reporting companies.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

The information to be reported under this item is not required of smaller reporting companies.

 

ITEM 4. CONTROLS AND PROCEDURES

 

 

(a)

DISCLOSURE CONTROLS AND PROCEDURES 

 

The Company’s management, including its Principal Executive Officer and Chief Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company’s management, including its Principal Executive Officer and Chief Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company’s disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures.

 

Page 23 of 26

 

 

(b)

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

 

The Company's Principal Executive Officer and Chief Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal controls over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. They have also concluded that there were no significant changes in the Company’s internal controls after the date of the evaluation.

 

PART II - OTHER INFORMATION

 

ITEM 1.        LEGAL PROCEEDINGS

 

NONE

 

ITEM 1A.     RISK FACTORS

 

The information to be reported under this item is not required of smaller reporting companies.

 

ITEM 2.        UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

NONE

 

ITEM 3.        DEFAULTS UPON SENIOR SECURITIES

 

NONE

 

ITEM 4.        MINE SAFETY DISCLOSURES

 

NONE

 

 

ITEM 5.        OTHER INFORMATION

 

NONE

 

 

 

 

 

 

 

 

Page 24 of 26

 

ITEM 6.        EXHIBITS

 

31.1*

Certification of Donna Vigilante, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

   

31.2*

Certification of Andrea Young, Chief Financial Officer of the Company, pursuant to Section302 of the Sarbanes-Oxley Act of 2002

   

32*

Certifications of Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

   

101.INS*

Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.

   

101.SCH*

Inline XBRL Taxonomy Extension Schema Document.

   

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

   

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document.

   

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document.

   

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

   

104*

Cover Page Interactive Data File (Embedded within the inline XBRL document and included in Exhibit 101.1).

 

* Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

Page 25 of 26

 

SIGNATURES

 

 

In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

Date: November 5, 2026

UNITED-GUARDIAN, INC

 

(Registrant)
     
     
  By:

/S/ DONNA VIGILANTE

   

Donna Vigilante

   

President

     
  By:

/S/ ANDREA YOUNG

   

Andrea Young

   

Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Page 26 of 26